In summary, consistent with the results of study 1, BE administration improved genetically induced obesity and its related metabolic syndromes by the activation of TGR5 and FXR via the regulation of the GM and the plasma BA pool. The gene discussed is NR1H4; the disease is metabolic syndrome.